bioRxiv ScienceSearch

Biology subjects

Wilson, F. P.

Publications and source records attributed to Wilson, F. P..

3 recordsLinked to original sources

An atlas of healthy and injured cell states and niches in the human kidney

Understanding kidney disease relies upon defining the complexity of cell types and states, their associated molecular profiles, and interactions within tissue neighborhoods. We have applied multiple single-cell or -nucleus assays (>400,000 nuclei/cells) and spatial imaging technologies to a broad spectrum of healthy reference (n = 42) and disease (n = 42) kidneys. This has provided a high resolution cellular atlas of 100 cell types that include rare and novel cell populations. The multi-omic approach provides detailed transcriptomic profiles, epigenomic regulatory factors, and spatial localizations for major cell types spanning the entire kidney. We further identify and define cellular states altered in kidney injury, encompassing cycling, adaptive or maladaptive repair, transitioning and degenerative states affecting several segments. Molecular signatures of these states permitted their localization within injury neighborhoods using spatial transcriptomics, and large-scale 3D imaging analysis of [~]1.2 million neighborhoods provided linkages to active immune responses. These analyses further defined biological pathways relevant to injury niches, including signatures underlying the transition from reference to predicted maladaptive states that were associated with a decline in kidney function during chronic kidney disease. This human kidney cell atlas, including injury cell states and neighborhoods, will be a valuable resource for future studies.

genomics

Multiscale PHATE Exploration of SARS-CoV-2 Data Reveals Multimodal Signatures of Disease

1The biomedical community is producing increasingly high dimensional datasets, integrated from hundreds of patient samples, which current computational techniques struggle to explore. To uncover biological meaning from these complex datasets, we present an approach called Multiscale PHATE, which learns abstracted biological features from data that can be directly predictive of disease. Built on a continuous coarse graining process called diffusion condensation, Multiscale PHATE creates a tree of data granularities that can be cut at coarse levels for high level summarizations of data, as well as at fine levels for detailed representations on subsets. We apply Multiscale PHATE to study the immune response to COVID-19 in 54 million cells from 168 hospitalized patients. Through our analysis of patient samples, we identify CD16hi CD66blo neutrophil and IFN{gamma}+GranzymeB+ Th17 cell responses enriched in patients who die. Further, we show that population groupings Multiscale PHATE discovers can be directly fed into a classifier to predict disease outcome. We also use Multiscale PHATE-derived features to construct two different manifolds of patients, one from abstracted flow cytometry features and another directly on patient clinical features, both associating immune subsets and clinical markers with outcome.

bioinformatics

Generating hard-to-obtain information from easy-to-obtain information: applications in drug discovery and clinical inference

In many important contexts involving measurements of biological entities, there are distinct categories of information: some information is easy-to-obtain information (EI) and can be gathered on virtually every subject of interest, while other information is hard-to-obtain information (HI) and can only be gathered on some of the biological samples. For example, in the context of drug discovery, measurements like the chemical structure of a drug are EI, while measurements of the transcriptome of a cell population perturbed with the drug is HI. In the clinical context, basic health monitoring is EI because it is already being captured as part of other processes, while cellular measurements like flow cytometry or even ultimate patient outcome are HI. We propose building a model to make probabilistic predictions of HI from EI on the samples that have both kinds of measurements, which will allow us to generalize and predict the HI on a large set of samples from just the EI. To accomplish this, we present a conditional Generative Adversarial Network (cGAN) framework we call the Feature Mapping GAN (FMGAN). By using the EI as conditions to map to the HI, we demonstrate that FMGAN can accurately predict the HI, with heterogeneity in cases of distributions of HI from EI. We show that FMGAN is flexible in that it can learn rich and complex mappings from EI to HI, and can take into account manifold structure in the EI space where available. We demonstrate this in a variety of contexts including generating RNA sequencing results on cell lines subjected to drug perturbations using drug chemical structure, and generating clinical outcomes from patient lab measurements. Most notably, we are able to generate synthetic flow cytometry data from clinical variables on a cohort of COVID-19 patients--effectively describing their immune response in great detail, and showcasing the power of generating expensive FACS data from ubiquitously available patient monitoring data. Bigger PictureMany experiments face a trade-off between gathering easy-to-collect information on many samples or hard-to-collect information on a smaller number of small due to costs in terms of both money and time. We demonstrate that a mapping between the easy-to-collect and hard-to-collect information can be trained as a conditional GAN from a subset of samples with both measured. With our conditional GAN model known as Feature-Mapping GAN (FMGAN), the results of expensive experiments can be predicted, saving on the costs of actually performing the experiment. This can have major impact in many settinsg. We study two example settings. First, in the field of pharmaceutical drug discovery early phase pharmaceutical experiments require casting a wide net to find a few potential leads to follow. In the long term, development pipelines can be re-designed to specifically utilize FMGAN in an optimal way to accelerate the process of drug discovery. FMGAN can also have a major impact in clinical setting, where routinely measured variables like blood pressure or heart rate can be used to predict important health outcomes and therefore deciding the best course of treatment.

bioinformatics